Union Bancaire Privee UBP SA lowered its stake in Boston Scientific Corporation (NYSE:BSX – Free Report) by 73.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,129 shares of the medical equipment provider’s stock after selling 173,105 shares during the period. Union Bancaire Privee UBP SA’s holdings in Boston Scientific were worth $2,585,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares during the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter worth $26,000. Main Street Financial Solutions LLC raised its holdings in Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC raised its holdings in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares during the last quarter. Finally, HUB Investment Partners LLC boosted its position in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares during the period. Institutional investors own 89.07% of the company’s stock.
Insider Transactions at Boston Scientific
In other news, Director Cheryl Pegus bought 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at $99,987.30. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 204,322 shares of company stock worth $9,939,221 over the last 90 days. 0.34% of the stock is currently owned by insiders.
Boston Scientific Price Performance
Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.
Boston Scientific declared that its Board of Directors has initiated a share repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. TD Cowen dropped their target price on shares of Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Truist Financial reduced their price target on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Citigroup lowered their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Finally, UBS Group dropped their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $71.62.
Check Out Our Latest Research Report on BSX
Boston Scientific Company Profile
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Read More
- Five stocks we like better than Boston Scientific
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
